AstraZeneca PLC (AZN)vsNovo Nordisk A/S (NVO)
AZN
AstraZeneca PLC
$166.14
-0.04%
HEALTHCARE · Cap: $252.33B
NVO
Novo Nordisk A/S
$43.24
+0.12%
HEALTHCARE · Cap: $205.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 437% more annual revenue ($329.43B vs $61.37B). NVO leads profitability with a 35.3% profit margin vs 17.0%. AZN appears more attractively valued with a PEG of 1.28. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
NVO
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$166.14
$29.67 discount
Intrinsic value data unavailable for NVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 42.5%
Generating 42.4B in free cash flow
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
2.1% revenue growth
Weak financial health signals
Expensive relative to growth rate
Earnings declined 20.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 35.3% and operating margin at 42.5%.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : NVO
The primary concerns for NVO are Revenue Growth, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
AZN profiles as a mature stock while NVO is a value play — different risk/reward profiles.
NVO carries more volatility with a beta of 0.34 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
NVO generates stronger free cash flow (42.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 58/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?